ArticleProceedings of SPIE--the International Society for Optical Engineering
Dose Prediction in Proton Cancer Therapy based on Density Maps from Dual-energy CT Using Joint Statistical Image Reconstruction.
Article in Proceedings of SPIE--the International Society for Optical Engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Accurate range prediction is critical in proton therapy to ensure conformal tumor dose. Currently, a safety margin of 2-3.5% is added to the end of the clinical target volume (CTV) to account for uncertainties in proton range estimated from single-energy CT (SECT) stopping-power ratio (SPR) maps. Our lab previously introduced and tested a joint statistical image reconstruction method (JSIR) using a basis-vector model (BVM) for SPR-map estimation which outperforms competing dual-energy CT (DECT) methods in both simulated and experimental scenarios. However, its impact on clinical proton-therapy treatment planning has yet to be demonstrated. In this study, we introduce a workflow for interfacing accurate JSIR-BVM density maps to a commercially-available Monte Carlo-based proton-therapy treatment-planning system, and compare the resultant dose-prediction errors to those of a standard SECT stoichiometric calibration technique for simulated and clinical patient cases. Percentage deviation from the ground-truth volume receiving 80% of the prescription dose within a 5 mm distal-ring region around the planning target volume was 2.6% for JSIR-BVM and 6.8% for SECT in the simulated case, showing a nontrivial risk of overshooting to surrounding tissues in the case of SECT. For the clinical head-and-neck cancer patient case, the mean errors in a similarly-defined ROI were 2.35% and 13.86%, for JSIR-BVM and SECT, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.